Home / Resources / Featured Services / Antisense Oligonucleotide Screening in iPSC-Derived Neurons

Human neuronal ASO evaluation

Antisense Oligonucleotide Screening in iPSC-Derived Neurons

Neurost provides project-specific antisense oligonucleotide screening in human iPSC-derived neurons for target knockdown, splice modulation, allele-selective strategies, dose-response studies, neuronal tolerability, and disease-relevant phenotype assessment. Programs can combine neuron differentiation support, experimental design, molecular and imaging assays, functional readouts, data analysis, and collaborative study refinement to address hit ranking, lead confirmation, and translational mechanism questions.

Discuss Your ASO Program Explore Capabilities

Scientific rationale

Measure ASO activity in the human neuronal context

ASO performance depends on sequence, chemistry, target transcript architecture, cellular uptake, intracellular trafficking, treatment schedule, and the biology of the selected neuron type. Immortalized or non-neural systems can answer early questions, but they may not reproduce transcript isoforms, maturation state, neuronal morphology, or disease-associated phenotypes that determine whether molecular activity is biologically meaningful.

Human iPSC-derived neurons provide a renewable experimental system in which candidate ASOs can be compared against untreated, vehicle, non-targeting, and relevant genetic controls. Depending on the project, the model may incorporate healthy-donor, patient-derived, or isogenic lines and a neuron subtype chosen for the target tissue or disease mechanism. Related Neurost capabilities include custom neural differentiation, custom CNS disease modeling, and iPSC-derived neural models.

Human genetics

Evaluate endogenous transcripts and, where appropriate, patient variants or phased alleles.

Neuronal biology

Connect molecular modulation with morphology, viability, activity, or a defined disease-relevant endpoint.

Decision-ready comparisons

Rank candidates across concentration, exposure time, specificity, persistence, and tolerability.

Screening capabilities

A modular path from assay setup to lead confirmation

The screening plan is configured around the ASO mechanism and the biological question. Modules can be combined for an initial candidate comparison or a deeper confirmation study; final methods, controls, sampling points, and acceptance criteria are agreed before execution.

01

Model and neuron selection

Select donor background, disease or isogenic controls, differentiation route, neuron subtype, culture format, maturation window, and plate scale according to target expression and endpoint requirements.

02

Candidate and dosing matrix

Compare candidate sequences, concentration ranges, exposure schedules, repeat dosing options, washout periods, and appropriate negative and positive controls.

03

Molecular pharmacology

Quantify total or allele-resolved RNA, splice products, transcript isoforms, and protein response where validated reagents and assay feasibility support the requested endpoint.

04

Neuronal response

Assess cell health and morphology, then add mechanism-aligned phenotypic or functional endpoints when a robust, interpretable neuronal phenotype is available.

Configure a Screening Matrix

Screening design

Build evidence in tiers, from activity to biological relevance

A tiered design limits the amount of mature neuronal material used before a candidate demonstrates a reproducible molecular effect. Each stage answers a defined question and establishes the evidence needed to advance, redesign, or stop a candidate.

Tier 1

Feasibility

Confirm target expression, define the quantification assay, test treatment handling, and establish a usable signal window in the selected neuronal culture.

Tier 2

Primary ranking

Compare candidates under a controlled concentration and time matrix using a primary molecular endpoint plus neuronal health measurements.

Tier 3

Lead confirmation

Retest selected candidates across independent differentiations and add protein, allele, durability, morphology, or functional endpoints as justified.

Assay strategy

Layered readouts for efficacy, selectivity, and neuronal fitness

Question Representative readouts Screening decision
Does the ASO engage the intended RNA mechanism? RT-qPCR, digital PCR where applicable, splice-junction analysis, transcript isoform measurement Rank activity and estimate concentration-response behavior
Is the desired allele or transcript preferentially modulated? Allele-resolved PCR or sequencing-based analysis when the target and informative variants permit Compare on-target selectivity across candidates
Does the molecular effect reach protein? Immunoblotting, immunocytochemistry, or other validated protein assays Confirm downstream translation of RNA modulation
Are neurons tolerating treatment? Cell viability, cytotoxicity markers, nuclear morphology, neurite integrity, neuron-marker imaging Separate pharmacology from nonspecific cellular stress
Is a relevant neuronal phenotype changed? High-content morphology, disease-specific imaging, calcium responses, or neuronal activity assays as feasible Prioritize candidates with biologically coherent effects

Assay availability and suitability depend on the neuron model, target biology, ASO chemistry, reagent performance, and project-specific validation. Neurost's related assay pages include high-content screening, MEA measurements of neurons, and neurotoxicity screening.

Study workflow

A stage-gated screening process

  1. 1

    Project definition and feasibility

    Review ASO mechanism, target transcript, cell background, neuron subtype, candidate count, controls, desired endpoints, and available starting materials.

  2. 2

    Model preparation and assay qualification

    Establish the agreed neuronal culture, confirm identity and morphology, assess target expression, and qualify the primary molecular and cell-health readouts.

  3. 3

    Primary ASO screen

    Apply the candidate and dosing matrix with prespecified controls, collect samples at agreed time points, and generate molecular activity and tolerability data.

  4. 4

    Hit confirmation

    Retest prioritized candidates with expanded concentration or time-course designs and add protein, selectivity, or phenotype endpoints where warranted.

  5. 5

    Integrated analysis and handoff

    Summarize methods, quality-control observations, processed results, candidate comparisons, limitations, and recommended follow-up questions.

Plan Your Study

Controls and quality framework

Separate ASO pharmacology from culture variability

Neuronal screens are most useful when biological controls, technical controls, and culture-quality observations are planned together. The final control set is mechanism-specific and is documented before treatment begins.

Treatment controls

Untreated or vehicle conditions, non-targeting ASO, and a positive or benchmark control when a suitable comparator exists.

Biological controls

Healthy-donor, disease, gene-corrected, or otherwise matched lines selected to support the specific causal comparison.

Culture acceptance observations

Morphology, neuron-marker expression, plating consistency, viability, and target-expression checks appropriate to the model and endpoint.

Replication strategy

Technical replicates support assay precision; independent cultures, differentiations, or lines are considered when the decision requires biological reproducibility.

Applications

Research questions supported by neuronal ASO screening

Target reduction

Compare RNase H-active candidates intended to lower a toxic or dosage-sensitive transcript and determine whether RNA and protein responses align.

Splice modulation

Evaluate exon inclusion, exon skipping, or correction of an aberrant splice event using junction-specific assays and downstream confirmation.

Allele-selective strategies

Test discrimination between alleles when sequence context, variant phasing, and analytical resolution permit a defensible comparison.

Phenotype rescue

Ask whether molecular modulation changes a reproducible disease-associated neuronal phenotype without compromising cell fitness.

Durability and washout

Follow molecular effects after treatment or washout to compare response persistence across prioritized candidates.

Orthogonal validation

Combine RNA, protein, imaging, and functional endpoints to reduce dependence on any single assay and strengthen lead-selection logic.

Candidate prioritization

Advance candidates using a balanced evidence profile

The strongest molecular effect is not automatically the strongest lead. A project-specific decision framework can weigh activity together with selectivity, neuronal fitness, durability, and consistency, while preserving the underlying data rather than compressing every result into a single score.

Activity

Magnitude and concentration dependence of the intended RNA effect

Selectivity

Allelic, isoform, or sequence discrimination supported by the assay

Tolerability

Cell-health and morphology findings at pharmacologically active exposure

Durability

Persistence of effect across the agreed treatment and washout window

Consistency

Agreement across replicates, cultures, lines, and orthogonal readouts

Deliverables

A transparent package for the next decision

Deliverables are defined in the study plan and can include experimental methods, culture and assay quality-control records, raw or processed datasets, concentration-response summaries, representative images, statistical outputs, and a final report. Interpretation distinguishes observed data from study limitations and proposed follow-up work.

Collaboration options

  • Standalone primary screening or staged primary-to-confirmation programs
  • Client-supplied or mutually selected cell lines and ASO materials
  • Custom endpoint panels aligned with mechanism and model feasibility
  • Milestone reviews before expanding into secondary assays
Request a Project Discussion

Related Research

Evidence for testing ASOs in patient-derived neurons

The following peer-reviewed papers were selected only after the publisher page explicitly identified the article as Creative Commons Attribution (CC BY). Together they illustrate human iPSC-derived neuronal testing, donor-specific neuronal disease models, and splice-switching ASO development strategy. The cited findings belong to the authors and are not presented as Neurost performance claims.

iPSC phenotype rescue

Human iPSC-derived neurons connect target reduction with neuronal phenotypes

Thakur, Lackinger, and colleagues evaluated an EMC10-lowering ASO strategy alongside human 22q11.2 deletion syndrome iPSC-derived neuronal models. Their design illustrates the value of combining target-expression measurements with neuronal arborization and activity-related assays when a candidate is expected to alter a cellular phenotype.

Thakur, Pratibha, et al. “An Antisense Oligonucleotide-Based Strategy to Ameliorate Cognitive Dysfunction in the 22q11.2 Deletion Syndrome.” eLife, vol. 13, 2025, RP103328. https://doi.org/10.7554/eLife.103328.3

CC BY 4.0 Publisher article and license statement

Donor-specific neurons

ASO testing in directly induced C9ORF72 patient neurons

Bauer and colleagues used neurons directly converted from fibroblasts of people with C9ORF72-associated ALS/FTD. ASO treatment was assessed against RNA foci, repeat-associated translation products, cell viability, and stress sensitivity, demonstrating how a donor-specific neuronal model can combine molecular and cellular endpoints for experimental therapy testing.

Bauer, Peter O., et al. “Neurons Induced From Fibroblasts of c9ALS/FTD Patients Reproduce the Pathology Seen in the Central Nervous System.” Frontiers in Neuroscience, vol. 13, 2019, article 935. https://doi.org/10.3389/fnins.2019.00935

CC BY 4.0 Publisher article and license statement

Splice switching

A development framework for neurological splice-switching ASOs

Zhang reviews variant-, exon-, and gene-specific splice-switching strategies for neurological disorders and specifically discusses human iPSCs and iPSC-derived neural cultures as tools for screening. The paper helps frame assay choices around exon inclusion or exclusion, productive isoform generation, disease mechanism, and translational model selection.

Zhang, Xiaochang. “Splice-Switching Antisense Oligonucleotides for Pediatric Neurological Disorders.” Frontiers in Molecular Neuroscience, vol. 17, 2024, article 1412964. https://doi.org/10.3389/fnmol.2024.1412964

CC BY 4.0 Publisher article and license statement

Translate the Evidence into a Study Plan

Frequently Asked Questions

Ask About Your ASO Study

Request a Quote

Fill out the form below, and our expert team will contact you to design your custom project and accelerate breakthrough innovations.

For Research Use Only. Not For Clinical Use.

Inquiry Basket